Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for cardiorenal conditions including hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(36,932) | $(56,342) | $(122,417) | $(128,864) |
| Net Loss Per Share (Basic/Diluted) | $(0.52) | $(1.13) | $(1.94) | $(2.68) |
| Operating Expenses | $41,131 | $60,106 | $132,324 | $140,636 |
| Research & Development | $31,450 | $53,985 | $107,607 | $124,012 |
| General & Administrative | $9,681 | $6,121 | $24,717 | $16,624 |
| Interest Income, Net | $4,195 | $3,774 | $9,908 | $11,779 |
| Cash, Cash Equivalents & Investments | $593,628 | $198,187 | $593,628 | $198,187 |
| Accumulated Deficit | $(424,935) | $(253,572) | $(424,935) | $(253,572) |
Note: Cash, cash equivalents, and investments as of September 30, 2025, totaled $593.6 million ($217.6 million cash/cash equivalents + $376.0 million investments).
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss for Q3 2025 decreased by $19.4 million compared to Q3 2024, primarily driven by a $22.5 million reduction in R&D expenses following the conclusion of pivotal clinical trials in Q2 2025.
- Capital Raising: The company significantly strengthened its liquidity position through two public offerings in 2025:
- March 2025: Sold ~14.9 million shares for net proceeds of ~$188.7 million.
- September 2025: Sold ~11.3 million shares for net proceeds of ~$269.6 million.
- ATM Termination: The company terminated its At-The-Market (ATM) equity offering agreement effective November 9, 2025, after raising approximately $27.3 million under the facility since April 2025.
- Increased G&A: General and administrative expenses increased by $3.6 million in Q3 2025 due to higher compensation costs and professional fees.
Outlook, Guidance, and Risks
- Regulatory Timeline: Management plans to submit a New Drug Application (NDA) for lorundrostat for hypertension in late 2025 or Q1 2026, based on positive results from the Launch-HTN and Advance-HTN pivotal trials.
- Clinical Pipeline:
- Explore-CKD: Positive Phase 2 results announced in June 2025 for hypertensive patients with CKD.
- Explore-OSA: Enrollment completed in Q3 2025 for a Phase 2 trial in obstructive sleep apnea; topline results expected in Q1 2026.
- Liquidity: Management believes current cash and investments ($593.6 million) are sufficient to fund operations for at least 12 months from the filing date.
- Risks:
- Government Shutdown: An ongoing U.S. government shutdown (as of October 1, 2025) may delay FDA review of the planned NDA.
- Trade Policy & Inflation: New tariffs and inflationary pressures could increase manufacturing and clinical trial costs.
- Tax Law Changes: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces new tax provisions, though management currently assesses no material impact on effective tax rates.
Key Investor Verification Points
- NDA Submission Timing: Verify the specific date of the planned NDA submission for hypertension given the potential impact of the government shutdown on FDA review cycles.
- Burn Rate vs. Cash Runway: Monitor quarterly cash burn rates to confirm the 12-month liquidity runway remains valid as commercialization preparations begin.
- Commercial Milestones: Review the Mitsubishi Tanabe license agreement for potential future milestone payments (up to $155 million) and royalty obligations upon product approval and sales.
- Explore-OSA Results: Await Q1 2026 topline data to assess the potential expansion of the addressable market beyond hypertension and CKD.